Scarica l'app Stockscreener
83.50
0.55%
0.415
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$83.08
Aprire:
$83.57
Volume 24 ore:
1.71M
Relative Volume:
0.39
Capitalizzazione di mercato:
$48.45B
Reddito:
$5.88B
Utile/perdita netta:
$1.34B
Rapporto P/E:
35.55
EPS:
2.3489
Flusso di cassa netto:
$799.60M
1 W Prestazione:
-0.93%
1M Prestazione:
-3.20%
6M Prestazione:
+11.16%
1 anno Prestazione:
+13.93%
Intervallo 1D:
$81.85
$84.09
Intervallo di 1 settimana:
$81.85
$85.19
Portata 52W:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
83.50 | 48.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
128.57 | 218.16B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
91.97 | 137.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.70 | 135.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.58 | 128.03B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Global Interventional Cardiology Devices Market is Predicted to Cross ~USD 30 Billion by 2034, Due to the Rising Cardiovascular Disease Burden | DelveInsight - GlobeNewswire Inc.
Edwards Lifesciences Resolves $140 Million Harpoon Medical Case - Bloomberg Law News
Edwards Lifesciences Completes Key Study on SAPIEN XT THV - TipRanks
Squarepoint Ops LLC Acquires 50,924 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Holocene Advisors LP Buys 1,223,460 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
934,449 Shares in Edwards Lifesciences Corporation $EW Bought by Hudson Bay Capital Management LP - MarketBeat
Hudson Bay Capital Management LP Invests $73.08 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE:EW) VP Donald Bobo Jr Sells 11,386 Shares - MarketBeat
Elevatus Welath Management Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Bellevue Group AG Sells 82,892 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Banque Transatlantique SA Purchases 24,575 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Heisz Stone Sells Shares of Edwards Lifesciences C - GuruFocus
Nebula Research & Development LLC Sells 16,819 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Purchased by DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main - MarketBeat
Edwards Lifesciences (NYSE:EW) VP Sells 11,340 Shares - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Glenview Trust co - MarketBeat
Citigroup Adjusts Edwards Lifesciences Price Target to $101 From $96, Maintains Buy Rating - marketscreener.com
State Street Corp Cuts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Insider Sold Shares Worth $2,153,373, According to a Recent SEC Filing - marketscreener.com
Daiwa Securities Group Inc. Acquires 24,475 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Bank of Nova Scotia Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Transcript : Edwards Lifesciences CorporationAnalyst/Investor Day - marketscreener.com
Scott Ullem Sells 7,700 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Vega Investment Solutions Has $28,000 Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Purchased by Natixis - MarketBeat
Edwards Lifesciences Corporation $EW Shares Acquired by Ossiam - MarketBeat
Edwards Lifesciences’ Markowitz sells $50k in stock By Investing.com - Investing.com Canada
Edwards Lifesciences Corporation $EW Stock Position Increased by 2Xideas AG - MarketBeat
Edwards Lifesciences’ Markowitz sells $50k in stock - Investing.com
Barclays Raises Edwards Lifesciences (EW) Price Target to $103.0 - GuruFocus
Leerink Partners Adjusts Edwards Lifesciences PT to $87 From $88, Maintains Market Perform Rating - marketscreener.com
WINTON GROUP Ltd Acquires 43,197 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock price target raised to $95 from $90 at Bernstein - Investing.com
Invesco Ltd. Decreases Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE:EW) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at Royal Bank Of Canada - MarketBeat
Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
Epoch Investment Partners Inc. Has $20.45 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW): Stifel Raises Price Target to $100 | - GuruFocus
Edwards Lifesciences (EW) Sees Analyst Target Price Increase Tod - GuruFocus
Amundi Raises Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
UBS Maintains Neutral Rating on Edwards Lifesciences (EW) and Ra - GuruFocus
Wells Fargo Maintains Edwards Lifesciences (EW) Overweight Recommendation - Nasdaq
Will Edwards Lifesciences’ (EW) Upgraded 2025–2026 Outlook Reshape Its Long-Term Growth Narrative? - Yahoo Finance
Edwards Lifesciences (EW) Analyst Rating Update for December 5, 2025 | EW Stock News - GuruFocus
Edwards Lifesciences (EW): Reassessing Valuation After Upbeat 2025–2026 Outlook and TAVR Growth Signals - Yahoo Finance
Edwards Lifesciences Sets Cautious Targets Yet Keeps Investors Interested - Finimize
Edwards Lifesciences : EW 2025 IC FINAL - marketscreener.com
Bernstein Adjusts Edwards Lifesciences Price Target to $95 From $90, Maintains Market Perform Rating - marketscreener.com
Wells Fargo Adjusts Price Target for Edwards Lifesciences (EW) | - GuruFocus
Edwards Lifesciences' Long-term Business Outlook Appears Achievable, RBC Says - marketscreener.com
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.57%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):